Search
Brotizolam
go.drugbank.com/drugs/DB09017ApprovedWithdrawnBrotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.
Rabies immune globulin, human
go.drugbank.com/drugs/DB11603ApprovedRecommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory
Citrulline
go.drugbank.com/drugs/DB00155InvestigationalNutraceuticalIt is also produced from arginine as a by-product of the reaction catalyzed by NOS family. Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.
Plasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigationalPlasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer need...
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
Atomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational[A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … [L6037] However, these stimulant medications are limited by dose-related side effects and concerns of abuse.
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalThe major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and no...
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalIt is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without
XL019
go.drugbank.com/drugs/DB05243InvestigationalAn IND for XL019 was filed by Exelixis in May 2007.